Letrozole Almus

Letrozole, the active ingredient in Letrozole Almus, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed to lower estrogen levels and treat hormone receptor‑positive breast cancer in postmenopausal women and may be used as part of adjuvant therapy after surgery.

GNH USA supplies Letrozole Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides bulk and packaged quantities to hospitals, pharmacies and procurement teams across global markets.

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer. - Hormone receptor‑positive breast cancer (postmenopausal): reduces tumor growth by lowering estrogen levels. - Adjuvant therapy for early‑stage breast cancer: decreases risk of recurrence after surgery. - Metastatic breast cancer (postmenopausal): helps control disease progression in advanced cases.

Letrozole may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint or muscle pain: arthralgia or myalgia. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing pain. - Increased cholesterol: elevated lipid levels.

Serious or Rare Side Effects: - Osteoporosis or bone fractures: reduced bone mineral density. - Severe liver injury: elevated transaminases or hepatitis. - Deep vein thrombosis or pulmonary embolism: clot formation in veins. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

Before initiating Letrozole, clinicians should consider several safety considerations. - Pregnancy contraindication: drug is classified Category X and must not be used in pregnant women. - Breastfeeding restriction: not recommended for nursing mothers due to potential drug transfer. - Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation. - Cardiovascular risk: evaluate lipid profile and manage hypercholesterolemia. - Drug interactions: review concomitant medications that affect CYP2A6 or estrogen levels. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Letrozole can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP2A6 inhibitors (e.g., ketoconazole): may increase letrozole plasma levels. - Estrogen‑containing hormone therapy: antagonizes therapeutic effect. - Tamoxifen: combined use may reduce effectiveness of both agents.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance anticoagulant effect, monitor INR. - Lipid‑lowering agents (statins): possible additive effect on liver enzymes. - CYP2A6 inducers (rifampin): may lower letrozole concentrations, reduce efficacy.